依替巴肽治疗非ST段抬高急性冠脉综合征的临床研究

摘要] 目的 观察依替巴肽治疗非ST段抬高急性冠脉综合征（NSTEACS）的疗效和安全性。方法 采用多中心随机单盲阳性药物对照的方法，84例NSTEACS患者随机分成试验组与对照组，试验组使用依替巴肽，对照组使用替罗非班，比较两者的疗效和副反应发生情况。结果 两组均能明显抑制血小板的聚集(P<0.05)，但两组对血小板的抑制程度无明显差异(P>0.05)；在降低NSTEACS患者心血管事件发生率上无明显差异，各观察指标发生率两组间比较P>0.05；两组主要副反应为轻度皮肤粘膜出血，实验组与对照组出血发生率分别为16.8%、19.0%(P>0.05)。结论 初步结果显示依替巴肽短期内（7天）治疗NSTEACS与替罗非班一样安全有效。

Clinical study of Eptifibatide in treating non-ST segment elevation acute coronary syndrome

Abstract] Object To observe the efficacy and safety of eptifibatide in treating non-ST segment elevation acute coronary syndrome. Method 84 patients were randomized into experimental and controlled group,experimental group received eptifibatide,controlled group received tirofiban,evaluating therapeutic effect and adverse reaction in two groups. Result eptifibatide and tirofiban can both inhibit platelet aggregation(P>0.05),there were no difference in cardiovascular events occurence in seven days between two groups(P>0.05).the main side effect was mucocutaneous bleeding,side effect occurred in 16.8% of the patients in experimental group versus 19.0% in controlled group(P>0.05).Conclusion eptifibatide is effective and safe in treating NSTEACS as tirofiban in short time(seven days).